Core Insights - Esperion announced two post-hoc analyses from the CLEAR Outcomes trial, demonstrating a 22% reduced risk of ischemic stroke for patients taking bempedoic acid compared to placebo [1][5] - The analyses also indicated that bempedoic acid reduced major adverse cardiovascular events (MACE) in high-risk patients with autoimmune or inflammatory diseases similarly to those without such conditions [1][5] Group 1: Clinical Findings - Bempedoic acid reduced the risk of ischemic stroke by 22% compared to placebo, with 90% of the 293 strokes recorded being ischemic [5] - Approximately 10% of the 13,970 participants in the CLEAR Outcomes trial had prior autoimmune and inflammatory diseases, which increase the risk of MACE [5] - Patients with autoimmune or inflammatory diseases experienced similar clinical benefits from bempedoic acid as those without these conditions [5] Group 2: Expert Commentary - Dr. Luke Laffin emphasized the elevated cardiovascular burden faced by patients with autoimmune and inflammatory diseases, highlighting the meaningful reductions in cardiovascular events provided by bempedoic acid [2] - Sheldon Koenig, President and CEO of Esperion, noted that the findings strengthen the evidence base for NEXLETOL as a therapy for cardiovascular risk reduction, particularly for statin-intolerant patients [2] Group 3: Product Indications - NEXLIZET and NEXLETOL are indicated to reduce the risk of major adverse cardiovascular events in adults at increased risk who cannot take statin therapy [5][6] - Bempedoic acid is part of these therapies aimed at lowering LDL-C levels in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH) [5][6]

Core Insights - Bempedoic acid has received strong endorsement from the AHA/ACC Multisociety Guideline for patients with statin intolerance and severe hypercholesterolemia, positioning it alongside PCSK9 mAb and ezetimibe for high-risk primary prevention and clinical ASCVD patients not at very high risk [1][2] - The guideline emphasizes the importance of early combination lipid-lowering therapy and reintroduces LDL-C goals, supporting the 'lower for longer is better' approach to cardiovascular risk reduction [1][5] Summary of Recommendations - Class 1 recommendations indicate that adults without a history of clinical ASCVD who experience statin-attributed muscle symptoms and are at high ASCVD risk should add bempedoic acid and/or ezetimibe to lower LDL-C to <70 mg/dL and non-HDL-C <100 mg/dL [3] - For adults with clinical ASCVD experiencing statin-attributed muscle symptoms, a reduced statin dose and the addition of bempedoic acid, ezetimibe, or a PCSK9 mAb are recommended to lower LDL-C and reduce ASCVD risk [3] - In adults with diabetes who have statin-attributed side effects, initiation of ezetimibe and/or bempedoic acid or a PCSK9 mAb is recommended to lower LDL-C and reduce ASCVD risk [3] - For adults with severe hypercholesterolemia on maximally tolerated statin therapy, the addition of ezetimibe, a PCSK9 mAb, and/or bempedoic acid is recommended to achieve LDL-C goals and reduce ASCVD risk [3] - Class 2a recommendations suggest that for adults with clinical ASCVD not at very high risk, it is reasonable to add bempedoic acid, ezetimibe, or a PCSK9 mAb to achieve LDL-C <70 mg/dL and non-HDL-C <100 mg/dL [3][7] Company Positioning - Esperion views the guideline recognition as a significant milestone that validates bempedoic acid as an evidence-based therapy for patients requiring additional LDL-C lowering or unable to tolerate statins, which strengthens its market position [2] - The endorsement is expected to accelerate the adoption and expand access to Esperion's products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) [2][10]

Summary of Esperion Therapeutics Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Industry**: Cardiovascular therapeutics - **Recent Performance**: Reported earnings with significant growth metrics Key Financial Highlights - **Total Revenue**: $408 million, representing a **38% year-over-year growth** [2] - **TRx Growth**: **34% year-over-year** and **11% quarter-over-quarter** growth in TRx [2] Acquisition Details - **Acquisition of Corstasis**: - Focused on a newly approved nasal loop diuretic, Enbumyst, which is **40 times more potent than furosemide** [3][6] - Expected to close in the **first week of April 2026** [3] - **Transaction Value**: $75 million upfront plus up to $180 million in milestones [18] - Financing through expanding existing term loan and monetizing Japanese royalties [19] Market Opportunity - **Target Markets**: - Expanding into cardiometabolic field, addressing unmet needs in heart failure [6][7] - Anticipated to reduce hospital readmission rates, which cost between **$12,000-$18,000** per heart failure readmission [13] - **Nasal Delivery System**: - Easy to use, potentially improving patient compliance and outcomes [14][16] Commercial Strategy - **Integration Plans**: - Pre-integration phase ongoing, with plans to leverage existing commercial infrastructure for product launch [23] - Focus on payer access and relationships with specialty pharmacies [30] - **Growth Strategy for Bempedoic Acid**: - Targeting **$1 billion plus opportunities** in the U.S. market [37] - Emphasis on maximizing NEXLIZET and NEXLETOL products [39] Competitive Landscape - **Guidelines and Market Position**: - Anticipation of new guidelines to provide a tailwind for bempedoic acid [37] - Highlighting unique outcomes data to differentiate from competitors [40][41] International Markets - **Partnerships**: - Strong performance reported by Daiichi Sankyo in Europe, particularly in Germany and the UK [57][61] - Otsuka in Japan showing promising sales, with over **700 representatives** promoting the drug [61] Future Outlook - **Vision 2040**: - Focus on growing the bempedoic acid franchise, business development, and pipeline expansion [78] - Upcoming clinical trials for ESP-2001 targeting primary sclerosing cholangitis [79] - Plans to explore kidney-related therapies, complementing heart failure treatments [80] Financial Health - **Cash Position**: - Ended the year with **$168 million** in cash, with ongoing improvements to the balance sheet [72] - Commitment to deleveraging while maintaining growth [75] Conclusion - Esperion Therapeutics is positioned for significant growth through strategic acquisitions, a robust product pipeline, and a strong commercial strategy aimed at addressing unmet needs in cardiovascular care. The company anticipates continued success in 2026, building on the momentum from 2025.

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $168.4 million, a 144% increase year-over-year [16] - U.S. net product revenue was $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [16] - Collaboration revenue surged to $124.7 million, a 232% increase compared to $37.6 million in Q4 2024, driven by a one-time payment of $90 million from Otsuka [16] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [15] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [7] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [7] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in Q4 royalty revenue compared to Q4 2024, expanding access to 30 countries [9] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced Vision 2040, outlining long-term ambitions and a roadmap for growth, including the acquisition of Corstasis Therapeutics [5] - The acquisition of Corstasis is expected to enhance the company's portfolio with Enbumyst, a first-in-class intranasal diuretic, and expand its presence in the cardiometabolic market [11][14] - The company aims to grow its two franchises to multi-billion-dollar potential [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [8] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to support the use of bempedoic acid [8] - The company anticipates significant growth opportunities in the heart failure market with the launch of Enbumyst [13] Other Important Information - The company plans to fully leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst [14] - The transaction for the acquisition of Corstasis is expected to close in Q2 2026 [14] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are ready for the launch and will provide updates on the auto-injector after the deal closes [22][25] Question: Updates on ACC guidelines - Management expects the guidelines to be released a week before the ACC conference and is preparing a cross-functional plan for the medical community [28][32] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the European guidelines have positively influenced U.S. prescribing and anticipates similar effects from the upcoming U.S. guidelines [39][44] Question: Triple combination products and market research - Management indicated high excitement for the triple combination therapy and clarified that it does not muddy the messaging around statin intolerance [61][62] Question: Corstasis clinical obligations and updates - There are minimal post-market obligations for Enbumyst, and management does not expect them to significantly impact operations [70] Question: Risks of concessions in 2026 - Management stated they do not foresee the need for concessions, emphasizing strong coverage and outcomes data [56]

Financial Data and Key Metrics Changes - The company reported total revenue of $168.4 million for Q4 2025, an increase of 144% year-over-year [16] - U.S. net product revenue reached $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [16] - Collaboration revenue surged to $124.7 million, a 232% increase compared to $37.6 million in Q4 2024, driven by a one-time payment of $90 million from Otsuka [16] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [15] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [7] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [7] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in fourth quarter royalty revenue compared to Q4 2024, expanding access to 30 countries [9] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced its Vision 2040 strategy, aiming for long-term growth and the acquisition of Corstasis Therapeutics to enhance its portfolio [5] - The acquisition of Corstasis is expected to provide global rights to Enbumyst, a first-in-class intranasal diuretic, expanding the company's presence in the cardiometabolic market [11][12] - The company plans to leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst and accelerate revenue contribution [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [8] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to positively impact the company's products [8] - Management emphasized the importance of the upcoming U.S. guidelines and their potential to enhance awareness and prescribing of bempedoic acid [35][44] Other Important Information - The company anticipates completing clinical and regulatory requirements for its triple combination programs by 2027 [8] - The planned acquisition of Corstasis is expected to close in Q2 2026, further strengthening the company's market position [14] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are prepared for the launch and have sufficient capacity for the product [23] Question: Updates on ACC guidelines - Management expects the guidelines to be released a week before the ACC conference and is preparing a comprehensive plan for the medical community [29][32] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the sentiment from U.S. physicians is positive regarding the European guidelines, which could lead to increased awareness and prescribing [42][44] Question: Triple combination product label expectations - Management indicated that the label for the triple combination will not carry outcomes data but will still be well-received by physicians [49] Question: Collaboration revenue guidance for 2026 - Management highlighted that collaboration revenue will be influenced by ongoing partnerships and the ramp-up of manufacturing [51] Question: Risks of additional concessions in 2026 - Management stated they do not foresee the need for concessions, as they have strong coverage and outcomes data to support their products [56]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $168.4 million, a 144% increase year-over-year [15] - U.S. net product revenue was $43.7 million, up approximately 38% from $31.6 million in Q4 2024 [15] - Collaboration revenue surged to $124.7 million, a 232% increase driven by a one-time payment of $90 million from Otsuka [15] - The company ended 2025 with $167.9 million in cash and reduced debt by $55 million [14] Business Line Data and Key Metrics Changes - The U.S. bempedoic acid franchise saw strong prescription growth, with Q4 year-over-year sales increasing by 38% and retail prescription equivalents rising by 34% [5] - The number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET increased by nearly 25% [5] Market Data and Key Metrics Changes - Daiichi Sankyo Europe reported a 51% increase in fourth quarter royalty revenue compared to Q4 2024, expanding access to 30 countries [8] - The Japanese partner, Otsuka, successfully launched NEXLETOL in Japan, exceeding early market expectations [9] Company Strategy and Development Direction - The company introduced Vision 2040, outlining long-term ambitions and a roadmap for growth, including the acquisition of Corstasis Therapeutics [4] - The acquisition is expected to enhance the company's portfolio with Enbumyst, a first-in-class intranasal diuretic, and expand its presence in the cardiometabolic market [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued momentum into 2026, driven by strong reimbursement and favorable positioning in U.S. dyslipidemia guidelines [6] - The American College of Cardiology's recognition of the link between inflammation and cardiovascular disease is expected to support the use of bempedoic acid [6] Other Important Information - The company plans to fully leverage its commercial team's cardiovascular sales presence to scale adoption of Enbumyst and accelerate revenue contribution [12] - The transaction for the acquisition of Corstasis is expected to close in Q2 2026 [12] Q&A Session Summary Question: Capacity and next steps for Corstasis - Management confirmed they are ready for a full-scale launch and will provide updates on the auto-injector after the deal closes [20][24] Question: Updates on ACC guidelines - Management anticipates the guidelines will be released a week before the ACC conference and is preparing a comprehensive plan for outreach [28][30] Question: Impact of EU guidelines on U.S. prescribing - Management noted that the European guidelines have positively influenced U.S. prescribing and expects similar outcomes from the upcoming U.S. guidelines [40][42] Question: Triple combination product expectations - The triple combination therapy is expected to have high interest, with a focus on both statin intolerant patients and those requiring low-dose statins [60] Question: Corstasis clinical obligations - There are minimal post-market studies required for Enbumyst, which have been accounted for in the updated expense guidance [69] Question: Future sales force expansion - The sales team will expand modestly post-acquisition to ensure coverage of key settings, including heart failure clinics [39]

Core Insights - Esperion reported a total revenue growth of 21% year-over-year (Y/Y) to $403.1 million for FY25, with U.S. net product revenue increasing by 38% Y/Y to $159.6 million [1][14] - The company achieved a significant Q4 2025 total revenue growth of 144% Y/Y to $168.4 million, with U.S. net product revenue also growing approximately 38% Y/Y to $43.7 million [1][14] - Esperion announced an agreement to acquire Corstasis Therapeutics, which is expected to enhance its cardiovascular franchise and align with its long-term strategic vision, Vision 2040 [1][4][3] Financial Performance - For Q4 2025, total revenue was $168.4 million, compared to $69.1 million in Q4 2024, marking a 144% increase [14] - Full-year revenue for 2025 reached $403.1 million, up from $332.3 million in 2024, reflecting a 21% increase [14] - U.S. net product sales for Q4 2025 were $43.7 million, up from $31.6 million in Q4 2024, a 38% increase [22] - Collaboration revenue for Q4 2025 was $124.7 million, a 232% increase from $37.6 million in Q4 2024 [22] Market Expansion and Strategic Initiatives - The acquisition of Corstasis Therapeutics is aimed at expanding Esperion's cardiovascular product offerings, particularly with the FDA-approved Enbumyst nasal spray [4][5] - Esperion's U.S. cardiovascular business showed strong momentum, with retail prescription equivalents growing 34% Y/Y and 11.3% quarter-over-quarter [6] - The company is focused on deeper U.S. market penetration and geographic expansion through partnerships, with a goal to enhance its product offerings and market access [3][8] Research and Development - Esperion is advancing its R&D pipeline, including the nomination of ESP-2001 for the treatment of primary sclerosing cholangitis, which represents a potential market opportunity exceeding $1 billion annually [15] - The company plans to develop oral triple combination lipid-lowering tablets, expected to be commercialized in 2027, which could rival existing therapies [10][11] Operational Highlights - Esperion's cash and cash equivalents as of December 31, 2025, totaled $167.9 million, an increase from $144.8 million in 2024 [20] - The company reported a net income of $61.8 million for Q4 2025, compared to a net loss of $21.3 million in Q4 2024 [18][19] - Selling, general, and administrative expenses for Q4 2025 were $41.4 million, a 12% increase from $36.9 million in Q4 2024, primarily due to increased legal costs [22]

Summary of NewAmsterdam Pharma Conference Call Company Overview - **Company**: NewAmsterdam Pharma (NasdaqGM:NAMS) - **Event**: FY Conference on March 03, 2026 Key Industry Insights - **Market Size**: The unmet need for LDL-lowering therapies is significant, with an estimated 30 million patients requiring treatment. The latest data indicates that achieving LDL levels below 55 is crucial for reducing total mortality, expanding the target population for combination therapies [4][5] - **Lipid Market Growth**: The lipid market is experiencing substantial growth, particularly in the branded segment, driven by more aggressive treatment targets and guidelines. The introduction of oral therapies is expected to further accelerate this growth [10][11] Core Product Insights - **Obicetrapib**: NewAmsterdam's lead drug, obicetrapib, is positioned as a differentiated LDL-lowering therapy with several key benefits: - **LDL Reduction**: Comparable LDL reductions to injectable therapies, with a significant reduction in small LDL particles by 90% [6][14][45] - **HDL Increase**: A 150% increase in HDL levels, which is associated with a lower risk of diabetes and potential benefits in Alzheimer's disease prevention [6][14][19] - **Lp(a) Lowering**: A 50% reduction in Lp(a) levels, targeting a population that may not qualify for existing injectable therapies [7][36] Clinical Trial Highlights - **BROADWAY Trial**: Demonstrated a 21% MACE benefit at 12 months, with a consistent LDL-lowering effect. The trial's design aligns closely with the upcoming PREVAIL trial, which is expected to validate these findings [3][12][15][23] - **Future Trials**: The PREVAIL trial is anticipated to provide further evidence of obicetrapib's efficacy, with a focus on achieving a positive MACE benefit to ensure broad uptake among clinicians [21][30] Regulatory and Commercial Strategy - **European Launch**: NewAmsterdam plans to launch obicetrapib in Europe, with regulatory approval expected by the end of 2026. The partnership with Menarini is seen as advantageous for market entry and reimbursement strategies [21][61][63] - **Market Differentiation**: The company aims to position obicetrapib as the first Lp(a)-lowering therapy in Europe, which could enhance its competitive edge [60][61] Financial Insights - **Funding and Milestones**: NewAmsterdam has secured $730 million in financing, with expectations to achieve significant sales milestones through its partnership with Menarini [4][61] - **Market Potential**: The potential market for obicetrapib is vast, with estimates suggesting it could serve tens of millions of patients, especially as treatment guidelines evolve [79] Additional Considerations - **Alzheimer's Disease Focus**: The potential for obicetrapib to impact Alzheimer's disease is highlighted as a significant opportunity, with market research indicating strong motivation among patients for effective treatments [18][78] - **Diabetes Risk**: Unlike statins, obicetrapib has shown a reduction in the risk of new-onset diabetes, which is a critical differentiator in the LDL-lowering market [14][30] Conclusion NewAmsterdam Pharma is positioned to capitalize on the growing demand for effective LDL-lowering therapies through its innovative product, obicetrapib. The company's strategic focus on clinical validation, regulatory approval, and market differentiation is expected to drive its success in the competitive landscape of lipid management.

Summary of Esperion Therapeutics FY Conference Call Company Overview - **Company**: Esperion Therapeutics (NasdaqGM:ESPR) - **Focus**: Commercializing bempedoic acid (Nexletol) and bempedoic acid plus ezetimibe (Nexlizet) [2][5] - **Vision**: Vision 2040 aims to execute today while building for tomorrow, with a goal of sustainable profitability by 2026 [2][10] Financial Performance - **U.S. Net Sales**: Expected range of $156 million to $160 million, total revenue of $400 million to $408 million [5] - **Retail Prescriptions**: Grew 34% year-over-year [5] - **Cash Position**: Preliminary cash of $168 million [5] - **Revenue Growth**: Total revenue grew 60% year-over-year when excluding partner milestones [10] Market Opportunity - **Target Market**: Statin intolerance market valued over $70 million, expanded total addressable market (TAM) from 10 million to 70 million patients due to CLEAR Outcomes study [6][8] - **Physician Adoption**: 25% year-over-year growth in physicians prescribing the drug, with over 45,000 physicians currently writing prescriptions [7] Product Pipeline and Development - **Triple Combination Therapy**: In development, combining Nexlizet with low doses of atorvastatin and rosuvastatin, targeting LDL efficacy of 65% to 71% [3] - **ESP-2001**: A drug for primary sclerosing cholangitis, a high unmet need with a market opportunity exceeding $1 billion [19][20] - **Next-Generation ACLY Pipeline**: Focus on leveraging AI for high-throughput screening of compounds, with 500 compounds currently under consideration [18][19] Strategic Partnerships and Global Expansion - **Partnerships**: Collaborations with Daiichi Sankyo in Europe and Otsuka in Japan, with the latter showing strong initial sales [9][48] - **Global Market Presence**: Approved in 41 countries, with plans for further expansion in Canada, Israel, Australia, and New Zealand by the end of 2026 [9][15] Commercial Strategy - **Sales Force Expansion**: Increasing personal promotion efforts from 20,000 to 40,000 physicians and digital outreach from 60,000 to 80,000 physicians [25] - **Access and Reimbursement**: Achieved 90% coverage in both commercial and Medicare markets, with efforts to simplify prior authorization processes [36][37] Future Outlook - **Sustainable Profitability**: Targeting sustainable profitability by 2026, with a focus on reinvesting in the bempedoic acid franchise and pipeline development [51][52] - **Vision 2040 Goals**: Aiming for five marketed products by 2040, with a diversified multi-product portfolio [10][11] Key Challenges and Considerations - **Manufacturing Responsibilities**: Esperion handles manufacturing for both U.S. and non-U.S. markets, with expectations of improved gross margins as Daiichi Sankyo begins production [34][35] - **Market Competition**: Competing with larger companies for assets, focusing on financially viable acquisitions that are immediately accretive [54][55] Conclusion Esperion Therapeutics is positioned for significant growth with a strong financial foundation, a robust product pipeline, and strategic partnerships. The company aims to capitalize on the expanding market for lipid-lowering therapies while navigating challenges in manufacturing and competition.

Core Insights - Esperion's bempedoic acid has been recognized as a first-line therapy for lowering LDL-C in patients with peripheral artery disease (PAD) and diabetes, as highlighted in the 2025 American College of Cardiology (ACC) Scientific Statement [1][4] Group 1: Company Positioning - Esperion emphasizes the significance of aggressive LDL-C lowering in high-risk populations, reinforcing bempedoic acid's role in reducing cardiovascular and limb risks [2] - The company anticipates that bempedoic acid will be included in the upcoming U.S. dyslipidemia treatment guidelines from ACC/American Heart Association (AHA) in early 2026, following its endorsement in European guidelines [3] Group 2: Clinical Evidence - The ACC scientific statement incorporates data from the 2024 AHA Scientific Sessions, which demonstrated that bempedoic acid reduced major adverse limb events (MALE) by 36% compared to placebo in patients with pre-existing PAD [5] - Bempedoic acid is positioned as a safe and well-tolerated oral option for lowering LDL-C and reducing the risk of MALE in patients with PAD [5] Group 3: Product Indications - Bempedoic acid, as part of NEXLIZET and NEXLETOL, is indicated for reducing the risk of major adverse cardiovascular events in adults unable to take statin therapy [8] - NEXLIZET and NEXLETOL are also indicated for reducing LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) [8]